

MEETING AGENDA



Pharmacy and Therapeutics Committee

Virtual Meeting

October 15, 2024

12:00 PM - 5:00 PM

Zoom Registration Link - [AHCCCS P&T Zoom Registration](#)

TIME	TOPIC
12:00 PM	Welcome & Introductions: Suzanne Berman, RPH, AHCCCS Pharmacy Director
12:10 PM	Minutes Review & Vote - P&T June 18, 2024: Suzanne Berman, RPH, AHCCCS Pharmacy Director
12.15 PM	Fifteen Non- Supplemental Rebate Drug Classes: Clinical review by Umang Patel, PharmD, Prime <ol style="list-style-type: none">1. Anticonvulsants<ol style="list-style-type: none">Oral Public Testimony: NoneWritten Public Testimony: None2. Antifungals - Oral<ol style="list-style-type: none">Oral Public Testimony: NoneWritten Public Testimony: None3. Antifungals - Topicals<ol style="list-style-type: none">Oral Public Testimony: NoneWritten Public Testimony: None4. Antimigraine Agents - Triptans<ol style="list-style-type: none">Oral Public Testimony: NoneWritten Public Testimony: None5. Beta Blockers<ol style="list-style-type: none">Oral Public Testimony: NoneWritten Public Testimony: None6. BPH Treatments<ol style="list-style-type: none">Oral Public Testimony: NoneWritten Public Testimony: None7. Calcium Channel Blockers<ol style="list-style-type: none">Oral Public Testimony: NoneWritten Public Testimony: None

MEETING AGENDA



	<ul style="list-style-type: none">8. Contraceptives<ul style="list-style-type: none">a. Oral Public Testimony: Noneb. Written Public Testimony: None 9. Hereditary Angioedema Agents<ul style="list-style-type: none">a. Oral Public Testimony: Noneb. Written Public Testimony: None 10. HIV-AIDs<ul style="list-style-type: none">a. Oral Public Testimony:<ul style="list-style-type: none">i. Natalie Roseb. Written Public Testimony:<ul style="list-style-type: none">i. Kaitlin Nguyen 11. Leukotriene Modifiers<ul style="list-style-type: none">a. Oral Public Testimony: Noneb. Written Public Testimony: None 12. Movement Disorder Agents<ul style="list-style-type: none">a. Oral Public Testimony:<ul style="list-style-type: none">i. Mandeep Sohalb. Written Public Testimony: None 13. Phosphate Binders<ul style="list-style-type: none">a. Oral Public Testimony: Noneb. Written Public Testimony: None 14. Sedative Hypnotics<ul style="list-style-type: none">a. Oral Public Testimony:<ul style="list-style-type: none">i. Keith Powellb. Written Public Testimony: None 15. Topical Steroids by Potency - Low, Medium, High, & Very High Potency<ul style="list-style-type: none">a. Oral Public Testimony: Noneb. Written Public Testimony: None
2:15 PM	New Drug Reviews: Hind Douiki, PharmD, Magellan/Prime Therapeutics <ul style="list-style-type: none">1. Agamree - Vamorolone2. Fabhalta - Iptacopan3. Litfulo - Ritlecitinib4. Rezdifra - Resmetiron

MEETING AGENDA



	<ul style="list-style-type: none">a. Oral Public Testimony:<ul style="list-style-type: none">i. William Lam5. Rivfloza - Nedosiran6. Spevigo - Spesolimab7. Voydeya - Danicopan8. Wainua - Eplontersen9. Zilbrysq - Zilucoplana. Oral Public Testimony:<ul style="list-style-type: none">i. Paul Bromann
3:00 PM	Break & Executive Session: Amber Small, PharmD, Magellan/Prime Therapeutics
4:15 PM	Public Therapeutic Class Votes: Umang Patel/Amber Small, PharmDs, Magellan/Prime Therapeutics
	Biosimilar Update: None
4:45 PM	Meeting Adjournment Future Meeting Dates: January 25, 2025